Quantcast

Latest GlaxoSmithKline Stories

2014-08-05 08:35:30

New site is filled with information, patient testimonials, easy-to-use tools and real-world tips for people affected by COPD RESEARCH TRIANGLE PARK, N.C., Aug. 5, 2014 /PRNewswire/ -- Today GlaxoSmithKline plc (LSE/NYSE: GSK) announced the launch of the redesigned COPD.com website, which provides disease education, interactive tools, tips and inspirational testimonials from patients living with chronic obstructive pulmonary disease (COPD), for an up-close and personal look at managing and...

2014-07-27 12:20:59

LifeScienceIndustryResearch.com adds Latest Report on "Global and Chinese Vardenafil (CAS 224785-90-4) Industry, 2009-2019 Market Research Report" to its store. DALLAS, July 27, 2014 /PRNewswire-iReach/ -- This is a professional and in-depth market survey on Global and Chinese Vardenafil (CAS 224785-90-4) industry. The report firstly reviews the basic information of Vardenafil (CAS 224785-90-4) including its classification, application and manufacturing technology. The report then...

2014-07-25 08:25:20

DUBLIN, July 25, 2014 /PRNewswire/ -- Research and Markets has announced the addition of the "Global Nicotine Gum Market 2014-2018" report to their offering. http://photos.prnewswire.com/prnh/20130307/600769 Nicotine gum is a smoking cessation product that helps smokers to slowly overcome nicotine addiction. Nicotine is released by chewing the gum and is absorbed into the blood stream through the lining of the mouth, which helps smokers to slowly reduce their craving for nicotine. Nicotine...

2014-07-24 16:26:21

No. 1 Prescribed Allergy Treatment Ingredient(1) to be Available OTC PARSIPPANY, N.J., July 24, 2014 /PRNewswire/ -- GlaxoSmithKline plc (LSE/NYSE: GSK) today announced that the U.S. Food and Drug Administration (FDA) has approved Flonase® Allergy Relief (fluticasone propionate 50 mcg spray), containing the No. 1 prescribed allergy treatment ingredient(1), as an over-the-counter (OTC) treatment for temporary relief of the symptoms of hay fever or upper respiratory allergies.(2) Flonase®...

2014-07-24 12:27:40

While Expressing Concerns about Reimbursement, EU5 Payers Look Favorably on Identifying Anti-IL5 Therapy-Responsive Patients, According to Findings from Decision Resources Group BURLINGTON, Mass., July 24, 2014 /PRNewswire/ -- Decision Resources Group finds that, for the treatment of asthma, pulmonologists in the EU5 countries (France, Germany, Italy, Spain and the United Kingdom) hold a generally positive view of the first once-daily long-acting beta2 agonist/inhaled corticosteroid...

2014-07-23 08:30:55

LONDON, July 23, 2014 /PRNewswire/ -- Global healthcare company GSK reports Q2 results reflecting a business that is facing currency headwinds, increased price competition and supply disruptions to its Consumer business. However its CEO Sir Andrew Witty points out that the company is very much in transition, citing progress in the development pipeline as reason to be confident about long-term prospects as well as the investments being made to drive long-term growth. CFO...

2014-07-23 08:30:32

District Court Judge Orders Apotex to Immediately Recall the Authorized Generic from its Direct Customers and to Stop Selling and Supplying the Product PITTSBURGH, July 23, 2014 /PRNewswire/ -- Mylan Inc. (Nasdaq: MYL) today announced that the U.S. District Court for the District of New Jersey granted its motion for a temporary restraining order against Apotex Inc. and Apotex Corporation in litigation relating to Paroxetine CR, the authorized generic of GlaxoSmithKline's Paxil(®)...

2014-07-17 08:28:43

PITTSBURGH, July 17, 2014 /PRNewswire/ -- Mylan Inc. (Nasdaq: MYL) today announced that the U.S. District Court for the District of New Jersey granted its motion for a permanent injunction against GlaxoSmithKline (GSK) in relation to Paroxetine CR, the generic version of GSK's Paxil(®) CR. GSK is now precluded from supplying product to Apotex, which marketed the product as an authorized generic. Mylan had previously been awarded damages in the amount of $106,700,000 by the District...

2014-07-08 23:08:08

Matters Involving Ongoing Litigation to Be Discussed DALLAS (PRWEB) July 08, 2014 Parties involved in lawsuits regarding the anti-psychotic drug Risperdal are scheduled to meet in the Philadelphia Court of Common Pleas to hold a conference to discuss moving litigation forward, the national law firm of Baron and Budd reports. The plaintiffs in the lawsuits accuse Janssen Pharmaceuticals, as well as parent company Johnson & Johnson, of allegedly failing to properly warn users of...

2014-07-02 08:26:15

CARLSBAD, Calif., July 2, 2014 /PRNewswire/ -- Isis Pharmaceuticals, Inc. (NASDAQ: ISIS) announced today that it has earned a $1 million payment from GlaxoSmithKline (GSK) related to the advancement of its program to develop antisense drugs to treat hepatitis B virus (HBV). http://photos.prnewswire.com/prnvar/20130807/LA60006LOGO "Our collaboration with GSK has been very productive resulting in three novel antisense drugs in our pipeline. We look forward to continuing to advance...


Word of the Day
barghest
  • A goblin in English folklore, often appearing in the shape of a large dog and believed to portend imminent death or misfortune.
  • A ghost, wraith, hobgoblin, elf, or spirit.
The origin of 'barghest' is not known, but it may be from perhaps burh-ghest, town-ghost, or German Berg-geist (mountain spirit) or Bär-geist (bear-spirit).
Related